Shares of healthcare tech company Privia Health Group (NASDAQ:PRVA) jumped 3.4% in the morning session as investors ...

Shares of medical technology company Enovis Corporation (NYSE:ENOV) jumped 3.3% in the morning session after the stock gained ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Arbitrators cleared the way for the long-delayed $53 billion acquisition after Exxon tried to pre-empt the deal. 3M raised its full-year earnings outlook after beating expectations in the second ...

AI inference attacks drain enterprise budgets, derail regulatory compliance and destroy new AI deployment ROI.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

A company's earnings performance is important for value investors as well. For fiscal 2025, five analysts revised their earnings estimate higher in the last 60 days for GSK, while the Zacks Consensus ...

GSK is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 8.62; value investors should ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the August 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...